<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110562</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-023</org_study_id>
    <nct_id>NCT03110562</nct_id>
  </id_info>
  <brief_title>Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma</brief_title>
  <acronym>BOSTON</acronym>
  <official_title>A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study&#xD;
      will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety&#xD;
      of selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd) versus bortezomib&#xD;
      plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior&#xD;
      anti-multiple myeloma (MM) regimens. Crossover from the Vd Arm to a treatment that includes&#xD;
      selinexor (i.e., SVdX or SdX) will be allowed at the point of IRC-confirmed objective disease&#xD;
      progression per the IMWG criteria for patients in the Vd Arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Actual">February 18, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by IRC</measure>
    <time_frame>From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months)</time_frame>
    <description>PFS was defined as time from date of randomization until the first date of IRC-confirmed PD, per International Myeloma Working Group (IMWG) response criteria, or death due to any cause, whichever occurs first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of &gt;= 0.5 gram per deciliter (g/dL); b) serum M-protein increase &gt;= 1 g/dL if the lowest M-component was &gt;=5 g/dL; c) urine M-protein (absolute increase must be &gt;= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than [&gt;] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be &gt;=10%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) as Assessed by IRC</measure>
    <time_frame>From date of randomization until disease progression or death, whichever occurred first (maximum duration up to 75 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response Rates</measure>
    <time_frame>From date of randomization until disease progression or death, whichever occurred first (maximum duration up to 75 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of randomization to the date of death or censored date, whichever occurred first (maximum duration of 75 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as Assessed by IRC</measure>
    <time_frame>From the first documentation of response to the first documentation of PD or death or censored date, whichever occurred first (maximum duration up to 75 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-next-treatment (TTNT)</measure>
    <time_frame>From date of randomization to start of next anti-MM treatment or death, whichever occurs first (maximum duration of 75 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-response (TTR) as Assessed by IRC</measure>
    <time_frame>From date of randomization until the date of first IRC confirmed response (maximum duration up to 75 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade &gt;= 2 Peripheral Neuropathy Events</measure>
    <time_frame>From date of randomization up to 30 days after last dose of treatment (maximum duration of 75 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs</measure>
    <time_frame>From date of randomization up to 30 days after last dose of treatment (maximum duration up to 75 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Peripheral Neuropathy Measured by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-CIPN20 Instrument</measure>
    <time_frame>Up to 75 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>selinexor+bortezomib+dexamethasone (SVd)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Selinexor will be given on Days 1, 8, 15, 22, and 29 of each 35-day cycle. Bortezomib will be given Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bortezomib+dexamethasone (Vd)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bortezomib will be given Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles. For cycles ≥ 9, bortezomib will be given on Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles. For cycles ≥ 9, dexamethasone will be given on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>oral 100 mg dose</description>
    <arm_group_label>selinexor+bortezomib+dexamethasone (SVd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>subcutaneous dose of 1.3 mg/m2</description>
    <arm_group_label>bortezomib+dexamethasone (Vd)</arm_group_label>
    <arm_group_label>selinexor+bortezomib+dexamethasone (SVd)</arm_group_label>
    <other_name>Velcade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>oral dose of 20mg</description>
    <arm_group_label>bortezomib+dexamethasone (Vd)</arm_group_label>
    <arm_group_label>selinexor+bortezomib+dexamethasone (SVd)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed MM with measurable disease per IMWG guidelines as defined by&#xD;
             at least 1 of the following:&#xD;
&#xD;
               -  Serum M-protein ≥ 0.5 g/dL (&gt; 5 g/L) by serum protein electrophoresis (SPEP) or&#xD;
                  for immunoglobulin (Ig) A myeloma, by quantitative serum IgA levels; or&#xD;
&#xD;
               -  Urinary M-protein excretion at least 200 mg/24 hours; or&#xD;
&#xD;
               -  Serum free light chain (FLC) ≥ 100 mg/L, provided that the serum FLC ratio is&#xD;
                  abnormal.&#xD;
&#xD;
          2. Had at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens.&#xD;
             Induction therapy followed by stem cell transplant and consolidation/maintenance&#xD;
             therapy will be considered as 1 anti-MM regimen.&#xD;
&#xD;
          3. Documented evidence of progressive MM (based on the Investigator's determination&#xD;
             according to the modified IMWG response criteria) on or after their most recent&#xD;
             regimen.&#xD;
&#xD;
          4. Prior treatment with bortezomib or other Proteasome Inhibitor (PI) is allowed,&#xD;
             provided all of the following criteria are met:&#xD;
&#xD;
               -  Best response achieved with prior bortezomib at any time was ≥ PR and with the&#xD;
                  last PI (PI therapy (alone or in combination) was ≥ PR, AND&#xD;
&#xD;
               -  Participant did not discontinue bortezomib due to ≥ Grade 3 related toxicity, AND&#xD;
&#xD;
               -  Must have had at least a 6-month PI-treatment-free interval prior to Cycle 1 Day&#xD;
                  1 (C1D1) of study treatment.&#xD;
&#xD;
          5. Must have an ECOG Status score of 0, 1, or 2.&#xD;
&#xD;
          6. Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines.&#xD;
&#xD;
          7. Age ≥18 years.&#xD;
&#xD;
          8. Resolution of any clinically significant non-hematological toxicities (if any) from&#xD;
             previous treatments to ≤ Grade 1 by C1D1.&#xD;
&#xD;
          9. Adequate hepatic function within 28 days prior to C1D1.&#xD;
&#xD;
         10. Adequate renal function within 28 days prior to C1D1.&#xD;
&#xD;
         11. Adequate hematopoietic function within 7 days prior to C1D1.&#xD;
&#xD;
         12. Female patients of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening. Female patients of childbearing potential and fertile male patients who are&#xD;
             sexually active with a female of childbearing potential must use highly effective&#xD;
             methods of contraception throughout the study and for 3 months following the last dose&#xD;
             of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior exposure to a SINE compound (i.e. an XPO-1 inhibitor), including selinexor.&#xD;
&#xD;
          2. Prior malignancy that required treatment, or has shown evidence of recurrence (except&#xD;
             for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during&#xD;
             the 5 years prior to randomization.&#xD;
&#xD;
          3. Any concurrent medical condition or disease (e.g., uncontrolled active hypertension,&#xD;
             uncontrolled active diabetes, active systemic infection, etc.) that is likely to&#xD;
             interfere with study procedures.&#xD;
&#xD;
          4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or&#xD;
             antifungals within 1 week prior to C1D1.&#xD;
&#xD;
          5. Active plasma cell leukemia.&#xD;
&#xD;
          6. Documented systemic light chain amyloidosis.&#xD;
&#xD;
          7. MM involving the central nervous system.&#xD;
&#xD;
          8. Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes&#xD;
             (POEMS) syndrome.&#xD;
&#xD;
          9. Spinal cord compression.&#xD;
&#xD;
         10. Greater than Grade 2 neuropathy or ≥ Grade 2 neuropathy with pain at baseline,&#xD;
             regardless of whether or not the patient is currently receiving medication&#xD;
&#xD;
         11. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.&#xD;
&#xD;
         12. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy (including&#xD;
             investigational therapies) ≤ 2 weeks prior to C1D1. Localized radiation to a single&#xD;
             site at least 1 week before C1D1 is permitted. Glucocorticoids within 2 weeks of C1D1&#xD;
             are permitted. Patients on long-term glucocorticoids during Screening do not require a&#xD;
             washout period but must be able to tolerate the specified dexamethasone dose in this&#xD;
             study.&#xD;
&#xD;
         13. Prior autologous stem cell transplantation &lt; 1 month or allogeneic stem cell&#xD;
             transplantation &lt; 4 months prior to C1D1.&#xD;
&#xD;
         14. Active graft versus host disease (after allogeneic stem cell transplantation) at C1D1.&#xD;
&#xD;
         15. Pregnant or breastfeeding females.&#xD;
&#xD;
         16. Body Surface Area &lt; 1.4 m² at baseline, calculated by the Dubois or Mosteller method.&#xD;
&#xD;
         17. Life expectancy of &lt; 4 months.&#xD;
&#xD;
         18. Major surgery within 4 weeks prior to C1D1.&#xD;
&#xD;
         19. Active, unstable cardiovascular function:&#xD;
&#xD;
               1. Symptomatic ischemia, or&#xD;
&#xD;
               2. Uncontrolled clinically significant conduction abnormalities (e.g., patients with&#xD;
                  ventricular tachycardia on anti-arrhythmics are excluded; patients with&#xD;
                  first-degree atrioventricular block or asymptomatic left anterior fascicular&#xD;
                  block/right bundle branch block will not be excluded), or&#xD;
&#xD;
               3. Congestive heart failure of New York Heart Association Class ≥ 3 or known left&#xD;
                  ventricular ejection fraction &lt; 40%, or&#xD;
&#xD;
               4. Myocardial infarction within 3 months prior to C1D1.&#xD;
&#xD;
         20. Known active human immunodeficiency virus (HIV) infection or HIV seropositivity&#xD;
&#xD;
         21. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C&#xD;
             virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.&#xD;
&#xD;
         22. Any active gastrointestinal dysfunction interfering with the patient's ability to&#xD;
             swallow tablets, or any active gastrointestinal dysfunction that could interfere with&#xD;
             absorption of study treatment.&#xD;
&#xD;
         23. Any active, serious psychiatric, medical, or other conditions/situations that, in the&#xD;
             opinion of the Investigator, could interfere with treatment, compliance, or the&#xD;
             ability to give informed consent.&#xD;
&#xD;
         24. Contraindication to any of the required concomitant drugs or supportive treatments.&#xD;
&#xD;
         25. Patients unwilling or unable to comply with the protocol, including providing 24-hour&#xD;
             urine samples for urine protein electrophoresis at the required time points.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boca Raton Clinical Research (BRCR) Medical Center</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stormont Vail Health Care (Cotton O'Neil Cancer Center )</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Hematology</name>
      <address>
        <city>Danville</city>
        <state>Kentucky</state>
        <zip>40422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Care Cancer Center</name>
      <address>
        <city>Bolivar</city>
        <state>Missouri</state>
        <zip>65613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital Luckow Pavilion</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute at St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant-Forsyth Memorial Hospital</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Cancer Center of Oklahoma</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCOR AnMed Health Cancer Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Lakes Healthcare</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Limited and Mater Medical Research</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Krems, Department of Internal Medicine II</name>
      <address>
        <city>Krems</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Hietzing</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminen Hospital, Department of Internal Medicine I, Center for Oncology &amp; Hematology</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Augustinus Hospital</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment, Sveti Georgi Clinic of Clinical Hematology</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment, Sveti Ivan Rilski Clinic of Hematology</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Hematological Diseases, Clinic of Hematology, Dept. of Clinical Hematology</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center/ Alberta Health Services</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute / University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North East Cancer Centre Sudbury</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital / McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Hôtel-Dieu de Québec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Cancer Agency-Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7TI</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Center</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Praha 2</city>
        <state>Prague</state>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hopsital Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava, Dept. of Hematooncology</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Kralovske Vinohrady, Clinic of Internal Hematology</name>
      <address>
        <city>Prague</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Necker Children's Hospital, Department of Adult Hematology</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Center Departmental La Roche-Sur-Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Claude Huriez Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Lyon Hospital Center</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brabois Adults Hospital, University Hospital Center of Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital Center</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miletrie Hospital, University Hospital Center of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg, Department of Internal Medicine I</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Leverkusen gGmbH Medizinisxhe Klinik 3</name>
      <address>
        <city>Leverkusen</city>
        <state>North Rhine Westfalia</state>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Practice for Hematology and Oncology</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra General Hospital, Therapeutic Clinic</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evangelismos&quot;, Department of Hematology and Lymphoma</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patra</name>
      <address>
        <city>Pátra</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theageneion Cancer Hospital, Hematology Department</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54639</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, 1st Department of Internal Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>H-1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Szent Istvan and Szent laszlo Hospital, Department of Hematology and Stem Cell Transplantation</name>
      <address>
        <city>Budapest</city>
        <zip>H-1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, 3rd Department of Internal Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>H-1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaposi Mor Teaching Hospital, 2nd Department of Internal Medicine</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the University of Pecs, Department of Hematology</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Centre</name>
      <address>
        <city>Patna</city>
        <state>Bihar</state>
        <zip>800014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Centre</name>
      <address>
        <city>Thiruvananthapuram</city>
        <state>Kerala</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Aly Khan Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashta</state>
        <zip>400010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital and Research Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashta</state>
        <zip>400026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhaktivedanta Hospital</name>
      <address>
        <city>Thane</city>
        <state>Maharashtra</state>
        <zip>401107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMS &amp; SUM Hospital</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education &amp; Research (PGIMER)</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayanand Medical College &amp; Hospital</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRM Institute of Medical Sciences</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saveetha Medical College Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>602105</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Kuppuswamy Naidu Hospital</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asviratham Speciality Hospital</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yashoda Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Telengana</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George's Medical University</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netaji Subhash Chandra Bose Cancer Research Institute</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700094</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nil Ratan Sircar (NRS) Medical College</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700120</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TATA Memorial Centre</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700160</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110085</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petaẖ Tiqwa</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria of Terni</name>
      <address>
        <city>Terni</city>
        <state>Umbria</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <zip>60131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic S. Orsola-Malpighi, Department of Hematology, Oncology and Laboratory Medicine, Operative Unit of Hematology - Cavo</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Careggi, Department of Hematology</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital San Martino, IRCCA, Dept. of Integrative Cancer Therapies, Operative Unit of Clinical Hematology</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Niguerda Ca Granda, Department of Hematology and Oncology, Hematology Unit</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umberto I Polyclinic of Rome, Department of Cellular Biotechnology and Hematology, Hematology Center</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital San Giovanni Battista of Turin</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan Biziel University Hospital #2 in Bydgoszcz, Department of Hematology</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Healthcare Facility Municipal Hospital Group in Chorzow, Department of Hematology</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital in Krakow, Teaching Unit of the Hematology Department</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Teaching Hospital No.1 in Lublin, Department of Hematology-Oncology and Bone Marrow Transplantation</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John of Dukla Oncology Center of Lublin, Department of Hematology</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Institute of Medicine, Department of Internal Medicine and Hematology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz, Department of Hematology</name>
      <address>
        <city>Łódź</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyperclnical MedLife PDR Vulturului Brasov, Hematology Department</name>
      <address>
        <city>Braşov</city>
        <zip>500366</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colentina Clinical Hospital, Department of Hematology</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bucharest University Emergency Hospital, Department of Hematology</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.P. Botkin City Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.A. Semashko Central Clinical Hospital #2 under OJSC Russian Railways</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First I.P. Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.A. Almazov North-West Federal Medical Research Center, Chemotherapy of Oncohematology Diseases and Bone Marrow Transplantation Department #1</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia, Clinic of Hematology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology and Radiology of Serbia, Clinic of Medical Oncology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac, Clinic of Hematology</name>
      <address>
        <city>Kragujevac</city>
        <zip>34 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis, Clinic of Hematology and Clinical Immunology</name>
      <address>
        <city>Nis</city>
        <zip>18 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Vojvodina, Clinic of Hematology</name>
      <address>
        <city>Novi Sad</city>
        <zip>21 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of the Canary Islands</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalan Institute of Oncology (ICO) Badalona</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Infanta Leonor, Department of Hematology</name>
      <address>
        <city>Madrid</city>
        <zip>28301</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital of Salamanca, Department of Hematology</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen del Rocio (HUVR)</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkasy Regional Oncology Center, Regional Treatment and Diagnostic Hematology Center, Department of Hematology</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No.4 of Dnipro City Council, City hematology center</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BMT Kiev Center</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiev Cancer Institute</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine, Department of Hematology with Laboratory Group</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia M.I. Pyrohov Regional Clinical Hospital, Department of Hematology</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O.F. Herbachevskyi Regional Clinical Hospital, Hematology Department with Intensive Therapy Wards</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast Heatlh &amp; Social Care Trust Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Tayside Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff &amp; Vale University Health Board University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Leeds Teaching Hospitals NHS Trust St. James University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust Royal Leicester Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool &amp; Broadgreen University Hospital NHS Trust Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London North West Healthcare NHS Trust Northwick Park Hospital</name>
      <address>
        <city>London</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Wolverhampton NHS Trust New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <results_first_submitted>June 15, 2021</results_first_submitted>
  <results_first_submitted_qc>June 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2021</results_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed or Refractory Multiple Myeloma</keyword>
  <keyword>RRMM</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03110562/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03110562/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 165 sites in 21 countries.</recruitment_details>
      <pre_assignment_details>A total of 402 participants were enrolled, out of which 399 participants received study treatment. Based on progressive disease (PD) confirmed by the Independent Review Committee (IRC), participants in the Vd arm could crossover to a regimen that included selinexor: 1) SVd treatment (SVdX) for participants who tolerated bortezomib, or 2) SdX for participants who had significant tolerability issues with bortezomib. Data reported were based on primary analysis cut-off date (18-Feb-2020).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SVd Arm: Selinexor + Bortezomib + Dexamethasone</title>
          <description>Participants received a fixed oral dose of 100 milligrams (mg) selinexor tablets (5 tablets of 20 mg each) once weekly (QW) on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with subcutaneous (SC) injection of 1.3 milligrams per square meter (mg/m^2) bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone twice weekly (BIW) on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.</description>
        </group>
        <group group_id="P2">
          <title>Vd Arm: Bortezomib + Dexamethasone</title>
          <description>Participants received SC injection of 1.3 mg/m^2 bortezomib QW on Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles, followed by greater than or equal to (&gt;=) 9 cycles on Days 1, 8, 15, and 22 of each 35-day cycle, and received oral dose of 20 mg dexamethasone BIW on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles and for cycles &gt;= 9 on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but never treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population consisted of all participants who were randomized to the study treatment, regardless of whether or not they received the study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>SVd Arm: Selinexor + Bortezomib + Dexamethasone</title>
          <description>Participants received a fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg each) QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with SC injection of 1.3 mg/m^2 bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone BIW on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.</description>
        </group>
        <group group_id="B2">
          <title>Vd Arm: Bortezomib + Dexamethasone</title>
          <description>Participants received SC injection of 1.3 mg/m^2 bortezomib QW on Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles, followed by &gt;= 9 cycles on Days 1, 8, 15, and 22 of each 35-day cycle, and received oral dose of 20 mg dexamethasone BIW on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles and for cycles &gt;= 9 on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="195"/>
            <count group_id="B2" value="207"/>
            <count group_id="B3" value="402"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="9.56"/>
                    <measurement group_id="B2" value="66.7" spread="9.35"/>
                    <measurement group_id="B3" value="66.0" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="326"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="359"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) as Assessed by IRC</title>
        <description>PFS was defined as time from date of randomization until the first date of IRC-confirmed PD, per International Myeloma Working Group (IMWG) response criteria, or death due to any cause, whichever occurs first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of &gt;= 0.5 gram per deciliter (g/dL); b) serum M-protein increase &gt;= 1 g/dL if the lowest M-component was &gt;=5 g/dL; c) urine M-protein (absolute increase must be &gt;= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than [&gt;] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be &gt;=10%).</description>
        <time_frame>From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months)</time_frame>
        <population>Intent-to-Treat (ITT) population consisted of all participants who were randomized to the study treatment, regardless of whether or not they received the study treatment. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>SVd Arm: Selinexor + Bortezomib + Dexamethasone</title>
            <description>Participants received a fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg each) QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with SC injection of 1.3 mg/m^2 bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone BIW on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.</description>
          </group>
          <group group_id="O2">
            <title>Vd Arm: Bortezomib + Dexamethasone</title>
            <description>Participants received SC injection of 1.3 mg/m^2 bortezomib QW on Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles, followed by &gt;= 9 cycles on Days 1, 8, 15, and 22 of each 35-day cycle, and received oral dose of 20 mg dexamethasone BIW on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles and for cycles &gt;= 9 on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) as Assessed by IRC</title>
          <description>PFS was defined as time from date of randomization until the first date of IRC-confirmed PD, per International Myeloma Working Group (IMWG) response criteria, or death due to any cause, whichever occurs first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of &gt;= 0.5 gram per deciliter (g/dL); b) serum M-protein increase &gt;= 1 g/dL if the lowest M-component was &gt;=5 g/dL; c) urine M-protein (absolute increase must be &gt;= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than [&gt;] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be &gt;=10%).</description>
          <population>Intent-to-Treat (ITT) population consisted of all participants who were randomized to the study treatment, regardless of whether or not they received the study treatment. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.93" lower_limit="11.73" upper_limit="NA">Upper limit of 95% CI was not estimable due to low number of events.</measurement>
                    <measurement group_id="O2" value="9.46" lower_limit="8.11" upper_limit="10.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0075</p_value>
            <method>Stratified Log-rank Test</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.7020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5279</ci_lower_limit>
            <ci_upper_limit>0.9335</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR) as Assessed by IRC</title>
        <time_frame>From date of randomization until disease progression or death, whichever occurred first (maximum duration up to 75 months)</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response Rates</title>
        <time_frame>From date of randomization until disease progression or death, whichever occurred first (maximum duration up to 75 months)</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>From date of randomization to the date of death or censored date, whichever occurred first (maximum duration of 75 months)</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR) as Assessed by IRC</title>
        <time_frame>From the first documentation of response to the first documentation of PD or death or censored date, whichever occurred first (maximum duration up to 75 months)</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-next-treatment (TTNT)</title>
        <time_frame>From date of randomization to start of next anti-MM treatment or death, whichever occurs first (maximum duration of 75 months)</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-response (TTR) as Assessed by IRC</title>
        <time_frame>From date of randomization until the date of first IRC confirmed response (maximum duration up to 75 months)</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade &gt;= 2 Peripheral Neuropathy Events</title>
        <time_frame>From date of randomization up to 30 days after last dose of treatment (maximum duration of 75 months)</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs</title>
        <time_frame>From date of randomization up to 30 days after last dose of treatment (maximum duration up to 75 months)</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-reported Peripheral Neuropathy Measured by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-CIPN20 Instrument</title>
        <time_frame>Up to 75 months</time_frame>
        <posting_date>09/2024</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From date of randomization up to 30 days after last dose of treatment (up to 32 months )</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SVd Arm: Selinexor + Bortezomib + Dexamethasone</title>
          <description>Participants received a fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg each) QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with SC injection of 1.3 mg/m^2 bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone BIW on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death or sponsor decision to terminate the study.</description>
        </group>
        <group group_id="E2">
          <title>Vd Arm: Bortezomib + Dexamethasone</title>
          <description>Participants received SC injection of 1.3 mg/m^2 bortezomib QW on Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles, followed by &gt;= 9 cycles on Days 1, 8, 15, and 22 of each 35-day cycle, and received oral dose of 20 mg dexamethasone BIW on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles and for cycles &gt;= 9 on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death or sponsor decision to terminate the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia parainfluenzae viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Mixed anxiety and depressive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Reactive psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jatin Shah, MD</name_or_title>
      <organization>Karyopharm Therapeutics Inc.</organization>
      <phone>(617) 658-0600</phone>
      <email>jshah@karyopharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

